1-6 of 6
Chihunt Wong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Joshua Richter, Sheeba K. Thomas, Amrita Y Krishnan, Jacob P. Laubach, Adam D. Cohen, Suzanne Trudel, Luciano J. Costa, Nizar J. Bahlis, Peter A. Forsberg, Rayan Kaedbey, Rafael Fonseca, Andrew Spencer, Paula Rodríguez-Otero, Maria-Victoria Mateos, Chihunt Wong, James Cooper, Tulika Tyagi, Rin Nakamura, Voleak Choeurng, Alexander M. Lesokhin
Journal: Blood
Blood (2024) 144 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2024-199542
Published: 2024
Journal Articles

Quantitative Pharmacology for Dose and Regimen Determination of Cevostamab Monotherapy in Relapsed/Refractory Multiple Myeloma

Monica Susilo, Romina Dokhaei, Logan Brooks, Shweta Vadhavkar, Wenyu Liu, Tulika Tyagi, Chihunt Wong, Divya Samineni
Journal: Blood
Blood (2024) 144 (Supplement 1): 7065.
https://doi.org/10.1182/blood-2024-204717
Published: 2024
Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Alexander M Lesokhin, Joshua Richter, Suzanne Trudel, Adam D Cohen, Andrew Spencer, Peter A Forsberg, Jacob P Laubach, Sheeba K Thomas, Nizar J. Bahlis, Luciano J. Costa, Paula Rodriguez Otero, Maria-Victoria Mateos, Jesus G Berdeja, Rayan Kaedbey, Amrita Y. Krishnan, Rafael Fonseca, Voleak Choeurng, James Cooper, Teiko Sumiyoshi, Chihunt Wong, Simon J Harrison
Journal: Blood
Blood (2022) 140 (Supplement 1): 4415–4417.
https://doi.org/10.1182/blood-2022-157547
Published: 2022
Journal Articles

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodriguez Otero, Simon J Harrison, Chihunt Wong, Grant R. Goodman, Rin Nakamura, Voleak Choeurng, James Cooper, Maria-Victoria Mateos
Journal: Blood
Blood (2022) 140 (Supplement 1): 1363–1365.
https://doi.org/10.1182/blood-2022-159381
Published: 2022
Journal Articles

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Suzanne Trudel, Adam D Cohen, Amrita Y. Krishnan, Rafael Fonseca, Andrew Spencer, Jesús G. Berdeja, Alexander Lesokhin, Peter A Forsberg, Jacob P. Laubach, Luciano J. Costa, Paula Rodriguez-Otero, Rayan Kaedbey, Joshua Richter, Maria-Victoria Mateos, Sheeba K Thomas, Chihunt Wong, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Simon J Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 157.
https://doi.org/10.1182/blood-2021-147983
Published: 2021
Journal Articles

Bcl-2, Bcl-x L , and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

Delphine Mérino, Seong L. Khaw, Stefan P. Glaser, Daniel J. Anderson, Lisa D. Belmont, Chihunt Wong, Peng Yue, Mikara Robati, Belinda Phipson, Walter D. Fairlie, Erinna F. Lee, Kirsteen J. Campbell, Cassandra J. Vandenberg, Suzanne Cory, Andrew W. Roberts, Mary J. C. Ludlam, David C. S. Huang, Philippe Bouillet
Journal: Blood
Blood (2012) 119 (24): 5807–5816.
https://doi.org/10.1182/blood-2011-12-400929
Published: 2012
Includes: Supplemental data